SCHEMBL6502030

SCHEMBL6502030

O=C(Cl)c1ccccc1C1CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.47
ALDH1A1 P00352 3/20 0.42
ALOX15 P16050 1/20 0.42
CYP2D6 P10635 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
KMO O15229 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HPGD P15428 2/20 0.41
TSHR P16473 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ACMSD Q8TDX5 2/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
PTGS2 P35354 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31362737 0.98 PTGDR2 (0.45) PTGDR2ALDH1A1ALOX15CYP2D6SLC6A2
SCHEMBL16654184 0.90 ALDH1A1 (0.47) PTGDR2ALDH1A1ALOX15CYP2D6SLC6A2
SCHEMBL341578 0.85 PTGDR2 (0.50) PTGDR2ALDH1A1CYP2D6SLC6A2SLC6A4
SCHEMBL28794360 0.85 PTGDR2 (0.50) PTGDR2ALDH1A1CYP2D6SLC6A2SLC6A4
SCHEMBL30730923 0.83 PTGDR2 (0.53) PTGDR2ALDH1A1ALOX15CYP2D6SLC6A2
SCHEMBL1702632 0.83 PTGDR2 (0.49) PTGDR2ALDH1A1CYP2D6SLC6A2SLC6A4
SCHEMBL50486 0.83 PTGDR2 (0.53) PTGDR2ALDH1A1ALOX15CYP2D6SLC6A2
SCHEMBL4742961 0.82 PTGDR2 (0.47) PTGDR2ALDH1A1CYP2D6SLC6A2SLC6A4
SCHEMBL7882968 0.82 ESR2 (0.44) ALDH1A1ALOX15NPC1MEN1KMT2A
SCHEMBL1515853 0.81 PTGDR2 (0.47) PTGDR2ALDH1A1ALOX15CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 PTGDR2 301/4885ALDH1A1 3345/4885ALOX15 752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.